Menaquinone-4 exerts a protective effect against carbon tetrachloride-induced acute liver injury in mice by alleviating ferroptosis

Lu YE; Fan ZHAO; Qianqian HUANG; Jiayi ZHANG; Jianqing WANG

doi:10.12449/JCH240121

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 121-128

PDF( 2106 KB)

Menaquinone-4 exerts a protective effect against carbon tetrachloride-induced acute liver injury in mice by alleviating ferroptosis

DOI: 10.12449/JCH240121

Lu YE¹,
Fan ZHAO¹,
Qianqian HUANG^{2, 3},
Jiayi ZHANG¹,
Jianqing WANG^{1, 2, 3
,
,
,}

1.
Department of Pharmacy，Anhui Medical University，Hefei 230032，China
2.
Department of Pharmacy，The First Affiliated Hospital of Anhui Medical University，Hefei 230012，China
3.
Anhui Public Health Clinical Center，Hefei 230012，China

Research funding:

National Natural Science Foundation of China (82073566);

The Program of Excellent Young Talents in Universities of Anhui Province (gxyq2019014);

Clinical Pharmacy and Pharmacology （2020） ;

Anhui Public Health Clinical Center, Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ14);

Anhui Public Health Clinical Center, Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ06);

Anhui Public Health Clinical Center, Supported by North District Scientific Research and Cultivation Foundation of the First Affiliated Hospital of Anhui Medical University (2023YKJ11)

More Information

Corresponding author: WANG Jianqing， jianqingwang81@126.com （ORCID： 0000-0002-7935-9520）
Received Date: 2023-03-30
Accepted Date: 2023-05-29
Published Date: 2024-01-23

Abstract

Abstract

Objective To investigate whether menaquinone-4 （MK-4） can exert a protective effect against carbon tetrachloride （CCl₄）-induced acute liver injury （ALI） in mice by alleviating ferroptosis. Methods After adaptive feeding， adult male ICR mice， aged 8 weeks， were divided into Control group， MK-4 group， CCl₄ model group （6-hour， 12-hour， and 24-hour）， and MK-4+CCl₄ group （6-hour， 12-hour， and 24-hour）， with 6 mice in each group. The mice in the Control group were given intraperitoneal injection of an equal dose of corn oil； the mice in the MK-4 group were given intraperitoneal injection of 40 mg/kg MK-4 solution， followed by an equal dose of corn oil after 1 hour； the mice in the MK-4+CCl₄ group （6-hour， 12-hour， and 24-hour） were given intraperitoneal injection of 40 mg/kg MK-4 solution， and after 1 hour， the mice in this group and the CCl₄ model group （6-hour， 12-hour， and 24-hour） were given intraperitoneal injection of 0.3 mL/kg CCl₄ solution， with samples collected at 6， 12， and 24 hours. HE staining was used to observe the pathological changes of mouse liver； Prussian blue staining was used to observe iron accumulation in liver tissue； a biochemical analyzer was used to measure the serum levels of aspartate aminotransferase （AST） and alanine aminotransferase （ALT）； related kits were used to measure the levels of tissue iron content and the oxidative stress indices malondialdehyde （MDA） and glutathione （GSH） in liver homogenate； RT-PCR was used to measure the expression levels of ferroptosis marker genes （acyl-CoA synthetase long-chain family member 4 ［ACSL4］， prostaglandin-endoperoxide synthase 2 ［PTGS2］， and glutathione peroxidase 4 ［GPX4］） and iron metabolism-related genes （hemojuvelin ［HJV］， transferrin receptor 1 ［TFR1］， and ferroportin ［FPN］）， and Western blot was used to measure the protein expression level of GPX4. A one-way analysis of variance was used for comparison of continuous data between multiple groups， and the least significant difference t-test was used for further comparison between two groups. Results In the aging study， compared with the Control group， the CCl₄ model group （6-hour， 12-hour， and 24-hour） had significant increases in liver weight coefficient and the serum levels of ALT and AST （all P<0.05）， and HE staining also showed that liver injury gradually aggravated over time. Meanwhile， compared with the CCl₄ model group （6-hour， 12-hour， and 24-hour）， the MK-4+CCl₄ （12-hour） group had significant reductions in liver weight coefficient and the serum levels of ALT and AST （all P<0.05）， with a reduction in the necrotic area of liver tissue， and therefore， 12-hour mouse tissue samples were used for detection in the following study. Compared with the Control group， the CCl₄ group had a significant increase in MDA and a significant reduction in GSH （both P<0.05）， and compared with the CCl₄ group， the MK-4+CCl₄ group had a significant reduction in MDA and a significant increase in GSH （both P<0.05）. Compared with the Control group， the CCl₄ group had significant increases in the key ferroptosis indices ASCL4 and PTGS2 and a significant reduction in GPX4 （all P<0.05）； compared with the CCl₄ group， the MK-4+CCl₄ group had significant reductions in the mRNA expression levels of ASCL4 and PTGS2 and a significant increase in the mRNA expression level of GPX4 （all P<0.05）. Western blotting showed that compared with the Control group， the CCl₄ group had a significant reduction in the protein expression level of GPX4 （P<0.05）， and compared with the CCl₄ group， the MK-4+CCl₄ group had a significant increase in the protein expression level of GPX4 （P<0.05）. Prussian blue staining showed that compared with the Control group， the CCl₄ group had a significant increase in iron accumulation； after MK-4 intervention， compared with the CCl₄ group， the MK-4+CCl₄ group had a significant reduction in iron accumulation. As for the measurement of iron metabolism genes in mouse liver， compared with the Control group， the CCl₄ group had a significant increase in iron content， significant reductions in the mRNA expression levels of FPN and HJV， and a significant increase in the mRNA expression level of TFR1 （all P<0.05）； after protection with MK-4， there was a significant reduction in iron content， significant increases in the mRNA expression levels of FPN and HJV， and a significant reduction in the mRNA expression level of TFR1 （all P<0.05）. Conclusion MK-4 intervention in advance can alleviate CCl₄-induced ALI in mice， possibly by inhibiting ferroptosis and improving the expression of iron metabolism-related genes in mouse liver.
- Liver Failure， Acute,
- Ferroptosis,
- Menaquinone-4,
- Mice， Inbred ICR

FullText(HTML)

References(18)

References

[1]	SHRESTHA DB, BUDHATHOKI P, SEDHAI YR, et al. N-acetyl cysteine versus standard of care for non-acetaminophen induced acute liver injury: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 24: 100340. DOI: 10.1016/j.aohep.2021.100340.
[2]	BHAKUNI GS, BEDI O, BARIWAL J, et al. Animal models of hepatotoxicity[J]. Inflamm Res, 2016, 65( 1): 13- 24. DOI: 10.1007/s00011-015-0883-0.
[3]	LIANG DG, MINIKES AM, JIANG XJ. Ferroptosis at the intersection of lipid metabolism and cellular signaling[J]. Mol Cell, 2022, 82( 12): 2215- 2227. DOI: 10.1016/j.molcel.2022.03.022.
[4]	JIANG XJ, STOCKWELL BR, CONRAD M. Ferroptosis: Mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22( 4): 266- 282. DOI: 10.1038/s41580-020-00324-8.
[5]	LIN FY, CHEN WY, ZHOU JH, et al. Mesenchymal stem cells protect against ferroptosis via exosome-mediated stabilization of SLC7A11 in acute liver injury[J]. Cell Death Dis, 2022, 13( 3): 271. DOI: 10.1038/s41419-022-04708-w.
[6]	VERVOORT LM, RONDEN JE, THIJSSEN HH. The potent antioxidant activity of the vitamin K cycle in microsomal lipid peroxidation[J]. Biochem Pharmacol, 1997, 54( 8): 871- 876. DOI: 10.1016/s0006-2952(97)00254-2.
[7]	LI JR, LIN JC, WANG H, et al. Novel role of vitamin k in preventing oxidative injury to developing oligodendrocytes and neurons[J]. J Neurosci, 2003, 23( 13): 5816- 5826. DOI: 10.1523/JNEUROSCI.23-13-05816.2003.
[8]	MISHIMA E, ITO J, WU ZJ, et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor[J]. Nature, 2022, 608( 7924): 778- 783. DOI: 10.1038/s41586-022-05022-3.
[9]	DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
[10]	QIAN MY, LIU MY, TAO CL, et al. Research progress of macrophages death[J]. Chin J Immun, 2023, 39( 1): 204- 210. DOI: 10.3969/j.issn.1000-484X.2023.01.034. 钱敏雅, 刘满宇, 陶晨璐, 等. 巨噬细胞死亡方式的研究进展[J]. 中国免疫学杂志, 2023, 39( 1): 204- 210. DOI: 10.3969/j.issn.1000-484X.2023.01.034.
[11]	SAMRA YA, HAMED MF, EL-SHEAKH AR. Hepatoprotective effect of allicin against acetaminophen-induced liver injury: Role of inflammasome pathway, apoptosis, and liver regeneration[J]. J Biochem Mol Toxicol, 2020, 34( 5): e22470. DOI: 10.1002/jbt.22470.
[12]	SATO T, SCHURGERS LJ, UENISHI K. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women[J]. Nutr J, 2012, 11: 93. DOI: 10.1186/1475-2891-11-93.
[13]	YANG WS, SRIRAMARATNAM R, WELSCH ME, et al. Regulation of ferroptotic cancer cell death by GPX4[J]. Cell, 2014, 156( 1-2): 317- 331. DOI: 10.1016/j.cell.2013.12.010.
[14]	STOCKWELL BR, ANGELI JPF, BAYIR H, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171( 2): 273- 285. DOI: 10.1016/j.cell.2017.09.021.
[15]	PIETRANGELO A. Genetics, genetic testing, and management of hemochromatosis: 15 years since hepcidin[J]. Gastroenterology, 2015, 149( 5): 1240- 1251.e4. DOI: 10.1053/j.gastro.2015.06.045.
[16]	ZHANG L, LIAO YQ, XIA QC, et al. Ferroptosis regulatory signaling pathway and its research progress in related diseases[J]. Chin J Clin Pharmacol Ther, 2022, 27( 2): 227- 234. DOI: 10.12092/j.issn.1009-2501.2022.02.015. 张亮, 廖勇群, 夏秦川, 等. 铁死亡调控信号通路以及在相关疾病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27( 2): 227- 234. DOI: 10.12092/j.issn.1009-2501.2022.02.015.
[17]	YANG WS, STOCKWELL BR. Ferroptosis: Death by lipid peroxidation[J]. Trends Cell Biol, 2016, 26( 3): 165- 176. DOI: 10.1016/j.tcb.2015.10.014.
[18]	FENG H, STOCKWELL BR. Unsolved mysteries: How does lipid peroxidation cause ferroptosis[J]. PLoS Biol, 2018, 16( 5): e2006203. DOI: 10.1371/journal.pbio.2006203.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[4]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[5]	Lizhen ZHU, Xiaolei XU, ABUDUSALAMU Aini, Xiaojuan WANG, Hu ZHOU, Rui TANG, Haining FAN, Qian LU. Research advances in immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(5): 1197-1203. doi: 10.3969/j.issn.1001-5256.2023.05.031
[6]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[7]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[8]	Jin LEI, Linzhi ZHANG, Yinying LU, Bowen CHEN, Shi ZUO. Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(4): 880-882. doi: 10.3969/j.issn.1001-5256.2022.04.026
[9]	Kangwei LI, Ding WEI, Ruohan ZHANG, Xiao LI, Kaishan TAO. Application of chimeric antigen receptor T-cell immunotherapy in primary liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(10): 2387-2390. doi: 10.3969/j.issn.1001-5256.2022.10.036
[10]	Hanping WANG. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[11]	Guoming SHI, Yanzhi PEI, Pinxiang LU, Jun CAO, Jian ZHOU, Jia FAN. Immune checkpoint inhibitors for treatment of biliary malignant tumors[J]. Journal of Clinical Hepatology, 2022, 38(5): 998-1001. doi: 10.3969/j.issn.1001-5256.2022.05.005
[12]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[15]	Jingzhong OUYANG, Yanzhao ZHOU, Ruili ZHU, Zhengzheng WANG, Xun CHEN, Jinxue ZHOU, Qingjun LI. Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 925-930. doi: 10.3969/j.issn.1001-5256.2021.04.043
[16]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[17]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[18]	Wei JianYing, Sun Wei, Liu XiaoMin, Chen JingLong. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2320-2324. doi: 10.3969/j.issn.1001-5256.2020.10.035
[19]	Luo Kui, Sun Hang, Wu ChuanXin. Immunotherapy for biliary tract cancer: Current status and perspectives[J]. Journal of Clinical Hepatology, 2019, 35(12): 2837-2840. doi: 10.3969/j.issn.1001-5256.2019.12.043

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(6) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (344) PDF downloads(39)

Menaquinone-4 exerts a protective effect against carbon tetrachloride-induced acute liver injury in mice by alleviating ferroptosis

DOI: 10.12449/JCH240121

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Menaquinone-4 exerts a protective effect against carbon tetrachloride-induced acute liver injury in mice by alleviating ferroptosis

DOI: 10.12449/JCH240121

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content